China National Tobacco Corporation 2024 Results: Achieves Record High Tax and Profit Revenue of US$220.9 Billion

Mar.06
China National Tobacco Corporation 2024 Results: Achieves Record High Tax and Profit Revenue of US$220.9 Billion
Tobacco industry in 2024 achieves record high tax revenue and fiscal total, contributing to economic stability and growth.

On March 5, the Media Center of China National Tobacco Corporation (CNTC) announced that in 2024, China’s tobacco industry achieved a total industrial and commercial tax and profit revenue of RMB 1.6008 trillion (approximately $220.9 billion), marking a 5.0% year-on-year increase. The total fiscal revenue reached RMB 1.5446 trillion(approximately $213.9 billion), up 2.8% from the previous year. 

 

CNTC stated that both figures set new historical records, making significant contributions to stabilizing the overall economy, increasing national and local fiscal revenues, and promoting economic and social development.

 

China National Tobacco Corporation 2024 Results: Achieves Record High Tax and Profit Revenue of US$220.9 Billion
In 2024, the tobacco industry achieved a record high in total tax and fiscal revenue. | Image Source: Oriental Tobacco News

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

New Zealand Survey Finds Adult Daily Vaping Prevalence at 11.7%, Concentrated Among Youth and Disadvantaged Groups)
New Zealand Survey Finds Adult Daily Vaping Prevalence at 11.7%, Concentrated Among Youth and Disadvantaged Groups)
A survey report released by the Public Health Communication Centre Aotearoa shows that despite New Zealand implementing stricter vaping regulations in 2025, including a ban on disposable products and tighter flavour restrictions, daily vaping rates continue to rise. The research body urges close monitoring of behavioural changes following the new rules coming into force.
Dec.05 by 2FIRSTS.ai
Malaysia CID Endorses Nationwide Vape Ban Amid Rising Drug-Laced Vape Cases
Malaysia CID Endorses Nationwide Vape Ban Amid Rising Drug-Laced Vape Cases
Malaysia’s Federal Criminal Investigation Department (CID) has voiced support for a nationwide ban on vaping, particularly targeting drug-laced vape devices, to address rising abuse cases.
Oct.23 by 2FIRSTS.ai
Ispire and IKE Tech Welcome FDA Enforcement Boost, Highlight Need for Tech-Based Controls
Ispire and IKE Tech Welcome FDA Enforcement Boost, Highlight Need for Tech-Based Controls
Ispire Technology and IKE Tech issued statements after the U.S. FDA received Congressional funding and directives to strengthen enforcement against illicit vaping products. The companies emphasized updated guidance, multi-agency coordination and the role of blockchain and age-verification technologies in preventing illegal imports and protecting youth.
Nov.20
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Bangladesh Tobacco Control Group Urges Reversal of Philip Morris Nicotine Pouch Factory Approval
Advocates say the economic authority’s decision contradicts national health goals and violates a Supreme Court directive banning new tobacco ventures.
Oct.27 by 2FIRSTS.ai
Japan Tobacco Expands Ploom Aura EVO Menthol Line With Two New Products and One Upgraded Blend
Japan Tobacco Expands Ploom Aura EVO Menthol Line With Two New Products and One Upgraded Blend
Japan Tobacco Inc. (JT) has added two new EVO sticks, Evo Black Menthol and Evo Fresh Mint, to its Ploom Aura lineup and reformulated Evo Cold Menthol, creating a menthol range with three distinct levels of cooling intensity and flavor profile.
Dec.01 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai